Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NSE India Stock Exchange  >  Biocon Limited    BIOCON   INE376G01013

BIOCON LIMITED

(BIOCON)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Biocon : India's Biocon Says Itolizumab Receives DGCI Approval For Use In Moderate To Severe COVID-19 Patients

share with twitter share with LinkedIn share with facebook
07/11/2020 | 06:39am EDT

July 11 (Reuters) - Biocon Ltd:

* SAYS DRUG ITOLIZUMAB RECEIVES DRUGS CONTROLLER GENERAL OF INDIA’S APPROVAL FOR ITS USE IN MODERATE TO SEVERE COVID-19 PATIENTS

* BIOCON SAYS ITOLIZUMAB WILL BE MANUFACTURED AND FORMULATED AS AN INTRAVENOUS INJECTION AT CO'S BIO-MANUFACTURING FACILITY IN BENGALURU, INDIA Further company coverage:

share with twitter share with LinkedIn share with facebook
Latest news on BIOCON LIMITED
08/03BIOCON : Tata Capital Growth Fund to Invest USD 30 million in Biocon Biologics f..
AQ
07/30BIOCON : Antibody drug lowers risk of death in elderly COVID-19 patients -Cuban ..
RE
07/24BIOCON : Q1FY21 Revenue at Rs 1,690 Cr, Up 14%, EBITDA at Rs 432 Cr, Net Profit ..
AQ
07/14EQUILLIUM : Clinical trial shows itolizumab reduces mortality in patients hospit..
AQ
07/14BIOCON : Presented Insights into Clinical Study That Enabled DCGI Approval of It..
AQ
07/13Health Care Up, But Biotech Stocks Down, On Value Bias -- Health Care Roundup
DJ
07/13BIOCON : Breakthrough Drug Itolizumab Receives DCGI Nod for its Use in Moderate ..
AQ
07/13NEWS HIGHLIGHTS : Top Company News of the Day
DJ
07/13NEWS HIGHLIGHTS : Top Company News of the Day
DJ
07/13NEWS HIGHLIGHTS : Top Company News of the Day
DJ
More news
Financials
Sales 2021 79 745 M 1 062 M 1 062 M
Net income 2021 10 840 M 144 M 144 M
Net Debt 2021 13 643 M 182 M 182 M
P/E ratio 2021 45,5x
Yield 2021 0,28%
Capitalization 488 B 6 491 M 6 501 M
EV / Sales 2021 6,29x
EV / Sales 2022 4,99x
Nbr of Employees 12 609
Free-Float 34,7%
Chart BIOCON LIMITED
Duration : Period :
Biocon Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOCON LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 413,47 INR
Last Close Price 413,80 INR
Spread / Highest target 25,7%
Spread / Average Target -0,08%
Spread / Lowest Target -45,6%
EPS Revisions
Managers
NameTitle
Siddharth Mittal Chief Executive Officer, Director & MD
Kiran Mazumdar-Shaw Executive Chairman
Indranil Sen Chief Financial Officer & Finance Controller
Manoj Kumar Pananchukunnath Head-Regulatory Sciences, Research & Development
Sandeep Nilkanth Athalye Head-Clinical Development & Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
BIOCON LIMITED40.89%6 491
GILEAD SCIENCES, INC.10.39%87 217
VERTEX PHARMACEUTICALS27.66%70 523
REGENERON PHARMACEUTICALS71.83%64 189
WUXI APPTEC CO., LTD.73.65%37 214
GENMAB A/S52.01%23 205